ImmunoDx AI

Executive Summary

ImmunoDx AI is a San Francisco-based diagnostics company leveraging artificial intelligence and machine learning to decode the immune system for improved disease detection and monitoring. Founded in 2020, the company analyzes complex immunological data to identify novel biomarkers and develop predictive, non-invasive diagnostic tests for autoimmune diseases, cancer, and infectious diseases. With $30 million in funding, ImmunoDx AI is building a platform that integrates multi-omics data and clinical informatics to deliver actionable insights. The company's AI-driven approach aims to revolutionize immunodiagnostics by enabling earlier and more accurate detection, potentially reducing the reliance on invasive procedures and improving patient outcomes. ImmunoDx AI is positioned at the intersection of AI and immunology, addressing significant unmet needs in personalized medicine and population health. The company's platform technology has broad applicability, and its early traction suggests strong potential for commercial success and clinical impact.

Upcoming Catalysts (preview)

• Q3 2026FDA breakthrough device designation for lead diagnostic test70% success
• Q4 2026Publication of key clinical validation study in peer-reviewed journal80% success
• Q1 2027Series B funding round or strategic partnership60% success